Clinical Trial Update: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-7339-003/LYNK-003 evaluated olaparib with or without bevacizumab against bevacizumab with a fluoropyrimidine in unresectable or metastatic colo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-04-02